This is Warren
We believe innovation starts when we stop to listen.
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.
Our R&D focus is on four therapeutic areas: infectious diseases, HIV, immunology/respiratory and oncology
Behind the science
Discover how we're getting ahead
AI and ML power better predictions for patient impact
Digital twin: using advanced technology to accelerate vaccine development
‘The roar I hear is the next stage of the rocket firing’: MAPS technology and the new age of vaccine development
Combining genetics and tech to double success rates
Getting ahead of infectious diseases with advanced technology
Tech for T-cells single cell RNA seq measures shifts in immune cells to pinpoint causes of disease
Fresh insights could finally help us tackle RSV
The ‘tripledemic’ will hit older people hard this winter – but there are things we can all do to reduce the impact
Life at GSK
How we help people thrive
Diversity, equity and inclusion
Positively impacting society and the planet
We are making our products affordable and available to more people around the world through responsible pricing, strategic access programmes and partnerships.
Global health and health security
We are committed to using our science, our partnerships, and the knowledge we’ve gained from addressing the world’s biggest health challenges to improve health globally.
We're committed to work towards a net zero, nature positive, healthier planet, with ambitious goals set for 2030 and 2045.
Diversity, equity and inclusion
Our work supports the health of all kinds of people. To meet our diverse patients' needs better, we need diversity in our clinical trials and to support our own people to thrive as part of an inclusive team.
Our culture guides our people to do the right thing and act on any concerns they have.
Ensuring the quality, safety and reliable supply of our products is critical to our purpose of uniting science, talent and technology to get ahead of disease together.
In the spotlight
We announced our full year and fourth quarter 2022 results on Wednesday 1 February
GSK on social
Until recently, medicines and vaccines were mainly tested on men. This has had a detrimental effect on the health outcomes of women around the world. However, attitudes are shifting: gsk.to/3LvMQcDTwitter @GSK Mar 19
We believe innovation starts when we stop to listen. Find out more about how we’re getting ahead of HIV together @FT gsk.to/FTHIVORGTwitter @GSK Mar 17
Researchers are pursuing new vaccines to fight bacteria and viruses that have eluded them for decades. gsk.to/3Jqf1qwTwitter @GSK Mar 16
Dana, Senior Specialty Account Specialist, Sales, and global lead for GSK’s Indigenous Peoples Association believes that having a diverse and multicultural workforce is vital to business success. Hear her story 👇QTwitter @GSK Mar 16
The UK has a big opportunity in life sciences, and we welcome today's #Budget2023 measures on medicines regulation and supporting the UK's life science SMEs which will help realise that opportunity.
While uncommon, #meningitis can progress very quickly and have devastating consequences. Learn more about the role of immunisation to get ahead of meningitis together.
We’re proud to be recognised by @CDP as a Supplier Engagement Leader in 2022 for our engagement with suppliers, and collaboration with industry peers to measure and reduce our impact on climate and nature: gsk.to/3TeEnw9 #CDPSupplyChain
Together, with our partners @TheKingsFund, we congratulate the winners of the 2023 #GSKIMPACTUK Awards! Check out the amazing work this year’s winners do to improve the health and wellbeing of their local communities 👉gsk.to/427sZX8fATwitter @GSK Mar 14
#News for #investors and #media: Today we have announced positive top-line Phase III data in #meningitis. gsk.com/en-gb/media/Twitter @GSK Mar 14
We partnered with @RareRevolutionM to elevate voices from the #myelofibrosis community as part of our effort to get #AheadTogether for patients with this rare #bloodcancer. Learn more from patients, caregivers and advocates in this #DigitalSpotlightTwitter @GSK Mar 11